FDA Statement Confirms Approval of Teva's Generic Version of Mylan's Epipen; Mylan Shares -0.4%, Teva +6.2%; BZ NOTE: Antares Pharma Has Exclusive License To Market Teva's Epinephrine in the U.S.
Benzinga Newsdesk